DLBCL After Allogeneic HCT in a Patient With Transformed DLBCL: Does It Matter Whether Relapse or PTLD?

Clin Lymphoma Myeloma Leuk. 2020 Apr;20(4):264-266. doi: 10.1016/j.clml.2019.12.002. Epub 2019 Dec 23.

Authors

Sunita Nathan¹, Mohammad Junaid Hussain², Jacqueline Baptista², Hyun Don Yun², Ankur Varma², Alexandra Vardouniotis³, Mallory Weber², Ira Miller⁴, Celalettin Ustun²

Affiliations

¹ Division of Hematology, Oncology and Cellular Therapy, Rush University Medical Center, Chicago, IL. Electronic address: Sunita_Nathan@rush.edu.
² Division of Hematology, Oncology and Cellular Therapy, Rush University Medical Center, Chicago, IL.
³ Department of Medical Laboratory Sciences, Rush University Medical Center, Chicago, IL.
⁴ Department of Pathology, Rush University Medical Center, Chicago, IL.

PMID: 32115402
DOI: 10.1016/j.clml.2019.12.002

No abstract available

Publication types

Case Reports
Letter

MeSH terms

Allografts
Hematopoietic Stem Cell Transplantation*
Humans
Lymphoma, Large B-Cell, Diffuse / blood
Lymphoma, Large B-Cell, Diffuse / pathology
Lymphoma, Large B-Cell, Diffuse / therapy*
Male
Middle Aged
Recurrence